Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Study of delayed responses among D30 non-responders to teclistamab finds 2 predictors: (1) achievement of D30 MR (vs. D30 SD or PD)(CI 3.64–163); and (2) D30 ALC (CI 1.06–8.29); PFS was the same for these delayed responders.”
Title: Predictors of Delayed Responses to Teclistamab in Multiple Myeloma After Initial Non-Response
Authors: Rahul Banerjee, Gurbakhash Kaur, Beatrice M. Razzo, Andrew J. Portuguese, Surbhi Sidana, Tiffany Richards, Ariel Grajales-Cruz, Shambavi Richard, Leyla Shune, Jack Khouri, Danai Dima, Hans C. Lee, Krina K. Patel, Oren Pasvolsky, Mariola Vazquez-Martinez, Doris K. Hansen, Aimaz Afrough, James A. Davis, Hamza Hashmi, Shebli Atrash, Christopher J. Ferreri, Kelley L. Julian, Megan M. Herr, Shonali Midha, Patrick Costello, Peter Forsberg, Andre de Menezes Silva Corraes, Yi Lin, Andrew J. Cowan, Larry D. Anderson Jr, Alfred L. Garfall
You can read the Full Article in the American Journal of Hematology.
You can find more posts featuring Robert Orlowski on OncoDaily.
